What is the 13F Pro Quality Score for CYRX?

13F Pro ranks Cryoport, Inc. (CYRX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CYRX's current score at https://13fpro.ai/research/CYRX (free sign-up required for the full ranking).

Which hedge funds own the most CYRX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CYRX include CADIAN CAPITAL MANAGEMENT,, MORGAN STANLEY, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CYRX as soon as new 13F filings post.

Where does 13F Pro source CYRX data?

All Cryoport, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cryoport, Inc. files with the SEC under CIK 1124524. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CYRX in?

Cryoport, Inc. (CYRX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CYRX research updated on 13F Pro?

CYRX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cryoport, Inc.(CYRX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1124524 CYRX stock profile & AI dashboard →

13F Pro Quality Score

59.7/100

Rank #901 of 2,879 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

87.0/100

Profitability

94.2/100

Balance Sheet

87.2/100

Earnings Quality

30.0/100

Free Cash Flow

16.2/100

Institutional Flow

35.3/100

Revenue Scale

23.1/100

Dilution Risk

23.8/100

CYRX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cryoport, Inc. (CYRX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CYRX at 59.7/100 on a 32-signal composite quality model, placing it at rank #901 of 2,879 stocks — the top half of the AI-ranked universe. CYRX scores in the top quartile across profitability (94.2), balance sheet strength (87.2), revenue growth (87.0). Areas of concern include free cash flow (16.2) and revenue scale (23.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 23.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cryoport, Inc. reports quarterly revenue of $47.8M, net income of $-10.5M, an operating margin of -20.1%. Top institutional holders of CYRX by reported 13-F value include CADIAN CAPITAL MANAGEMENT,, MORGAN STANLEY, BlackRock,, based on the most recent SEC filings. CYRX trades on the Nasdaq exchange and files with the SEC under CIK 1124524. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CYRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cryoport, Inc. directly from SEC EDGAR. Cryoport, Inc.'s 13F Pro composite quality score has ranged between 8 and 60 since 2021, currently 59.7 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Cryoport, Inc.

Quirks, history, and lore behind CYRX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare logistics company · listed on Nasdaq · specializes in temperature-controlled supply chain services for the life sciences industry.
2
The Numbers
A small-cap company with annual revenue in the range of a few hundred million dollars — not a giant, but a very specialized niche player with high growth ambitions.
3
The History
Founded in the early 2000s, it built its business around the idea that biological materials — cells, tissues, gene therapies — needed their own dedicated cold-chain infrastructure.
4
The Secret
Its core product is a dry-vapor nitrogen shipper that keeps cargo at ultra-low temperatures — we're talking colder than your freezer by a very, very long way.
5
The Lore
As cell and gene therapy boomed, so did this company — its client list reads like a who's who of biopharma and CAR-T therapy developers racing to ship living medicines to patients.
6
The Giveaway
If a life-saving cell therapy needs to travel cross-country at cryogenic temperatures, this Nashville-based logistics specialist — whose very name tells you exactly what it does — is probably making that happen.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$47.8M

Net Income

Q1 2026

$-10.5M

Free Cash Flow

Q1 2026

$-6.2M

Operating Margin

Q1 2026

-20.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+12.4% YoY

$176.2MFY 2025

FY22 $237.3MFY23 $168.7MFY24 $156.8MFY25 $176.2M

Net Income

+168.2% YoY

$78.3MFY 2025

FY22 $-37.3MFY23 $-99.6MFY24 $-114.8MFY25 $78.3M

Operating Income

+69.7% YoY

$-36.8MFY 2025

FY22 $-31.9MFY23 $-100.5MFY24 $-121.7MFY25 $-36.8M

EPS (Diluted)

+156.2% YoY

$1.40FY 2025

FY22 $-0.93FY23 $-2.21FY24 $-2.49FY25 $1.40

Total Assets

+8.7% YoY

$765.0MFY 2025

FY22 $1.04BFY23 $957.7MFY24 $703.5MFY25 $765.0M

Op. Cash Flow

+47.4% YoY

$-8.6MFY 2025

FY22 $-1.9MFY23 $-757.0KFY24 $-16.3MFY25 $-8.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$176.2M +12.4%	$156.8M -7.1%	$168.7M -28.9%	$237.3M +6.6%	$222.6M +182.9%	$78.7M
Net Income	$78.3M +168.2%	$-114.8M -15.2%	$-99.6M -166.8%	$-37.3M +86.5%	$-275.5M -742.8%	$-32.7M
Operating Income	$-36.8M +69.7%	$-121.7M -21.0%	$-100.5M -215.1%	$-31.9M -78.9%	$-17.8M +40.6%	$-30.0M
EPS (Diluted)	$1.40 +156.2%	$-2.49 -12.7%	$-2.21 -137.6%	$-0.93 +85.0%	$-6.18 -218.6%	$-1.94
Total Assets	$765.0M +8.7%	$703.5M -26.5%	$957.7M -7.8%	$1.04B -6.7%	$1.11B +101.5%	$552.4M
Operating Cash Flow	$-8.6M +47.4%	$-16.3M -2056.3%	$-757.0K +59.1%	$-1.9M -122.8%	$8.1M +154.7%	$-14.9M

AI Insight: CYRX Financial Trends

Revenue declined 36% from Q2 2024 peak of $75M to Q1 2026's $48M, while operating losses persist despite Q2 2025 net income spike.

• Revenue fell from $75M in Q2 2024 to $48M in Q1 2026, declining 36% over eight quarters.

• Operating income remained consistently negative, ranging from -$83M to -$7M across all reported quarters.

• Operating cash flow improved from -$8M in Q2 2024 to $4M in Q1 2026.

• Equity increased from $400M in Q2 2024 to $515M in Q2 2025 before moderating to $495M in Q1 2026.

⚠ Q2 2025 showed $105M net income anomaly amid otherwise consistent losses, suggesting one-time gain.

⚠ Revenue volatility with no clear recovery trend from the Q2 2024 peak of $75M.

AI Insight: CYRX Ratio Trends

Cryoport remains deeply unprofitable with operating margins stuck around -20% despite some improvement from the -110.8% trough in Q2 2024.

• Operating margin improved dramatically from -110.8% in Q2 2024 to -20.1% in Q1 2026, though still deeply negative.

• Net profit margin turned positive to 43.6% on TTM basis despite quarterly losses continuing through Q1 2026.

• ROIC remained consistently negative, ranging from -83.0% to -5.7% across all periods with no clear improvement trend.

⚠ Persistent operational losses with operating margins failing to reach positive territory despite two years of recovery.

⚠ Large gap between positive TTM net margin (43.6%) and negative quarterly margins suggests unsustainable one-off gains.

Get alerted when CYRX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cryoport, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CYRX

CADIAN CAPITAL MANAGEMENT, LP
$39.5M4,776,343 sh
MORGAN STANLEY
$37.9M4,576,730 sh
BlackRock, Inc.
$33.0M3,980,898 sh
MILLENNIUM MANAGEMENT LLC
$24.6M2,970,464 sh
VANGUARD CAPITAL MANAGEMENT LLC
$17.5M2,118,856 sh
FRED ALGER MANAGEMENT, LLC
$14.1M1,699,379 sh
Assenagon Asset Management S.A.
$12.4M1,495,683 sh
MAK CAPITAL ONE LLC
$11.8M1,423,265 sh
GEODE CAPITAL MANAGEMENT, LLC
$10.3M1,248,135 sh
MIROVA
$9.6M1,158,277 sh

Fund	Value	Shares
CADIAN CAPITAL MANAGEMENT, LP	$39.5M	4,776,343
MORGAN STANLEY	$37.9M	4,576,730
BlackRock, Inc.	$33.0M	3,980,898
MILLENNIUM MANAGEMENT LLC	$24.6M	2,970,464
VANGUARD CAPITAL MANAGEMENT LLC	$17.5M	2,118,856
FRED ALGER MANAGEMENT, LLC	$14.1M	1,699,379
Assenagon Asset Management S.A.	$12.4M	1,495,683
MAK CAPITAL ONE LLC	$11.8M	1,423,265
GEODE CAPITAL MANAGEMENT, LLC	$10.3M	1,248,135
MIROVA	$9.6M	1,158,277

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CYRX on your watchlist

Track score changes the day Cryoport, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CYRX a good stock to buy?

13F Pro's AI-powered analysis of Cryoport, Inc. (CYRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CYRX are available on the CYRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CYRX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CYRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cryoport, Inc.'s investment landscape.